 Wesley Nuffer
Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Students, Pharmacy | 15 | 2023 | 96 | 4.630 |
Why?
| | Education, Pharmacy | 16 | 2022 | 119 | 4.210 |
Why?
| | Community Pharmacy Services | 9 | 2022 | 43 | 3.700 |
Why?
| | Medication Therapy Management | 4 | 2019 | 72 | 2.180 |
Why?
| | Pharmacies | 5 | 2022 | 36 | 1.970 |
Why?
| | Problem-Based Learning | 4 | 2017 | 78 | 1.460 |
Why?
| | Pharmacists | 7 | 2021 | 247 | 1.380 |
Why?
| | Curriculum | 9 | 2023 | 917 | 1.350 |
Why?
| | Pharmacy | 4 | 2023 | 31 | 1.280 |
Why?
| | Hypoglycemic Agents | 7 | 2025 | 1220 | 1.170 |
Why?
| | Diabetes Mellitus, Type 2 | 8 | 2025 | 2441 | 1.140 |
Why?
| | Cinnamomum zeylanicum | 2 | 2024 | 2 | 1.100 |
Why?
| | Anti-Obesity Agents | 3 | 2016 | 53 | 1.070 |
Why?
| | Educational Measurement | 5 | 2020 | 262 | 0.970 |
Why?
| | Pharmaceutical Services | 3 | 2023 | 81 | 0.930 |
Why?
| | Receptors, Glucagon | 2 | 2014 | 27 | 0.910 |
Why?
| | Blood Glucose | 3 | 2024 | 2097 | 0.910 |
Why?
| | Cinnamomum aromaticum | 1 | 2024 | 1 | 0.900 |
Why?
| | Plant Preparations | 1 | 2024 | 32 | 0.880 |
Why?
| | Program Development | 4 | 2017 | 357 | 0.780 |
Why?
| | Diabetes Mellitus | 3 | 2024 | 1001 | 0.740 |
Why?
| | Liraglutide | 3 | 2016 | 29 | 0.730 |
Why?
| | Glucagon-Like Peptide 1 | 3 | 2015 | 112 | 0.640 |
Why?
| | Models, Educational | 1 | 2018 | 88 | 0.570 |
Why?
| | Perception | 2 | 2017 | 340 | 0.550 |
Why?
| | Program Evaluation | 6 | 2020 | 875 | 0.470 |
Why?
| | Drugs, Investigational | 1 | 2014 | 32 | 0.450 |
Why?
| | Rural Health Services | 2 | 2012 | 111 | 0.430 |
Why?
| | Writing | 2 | 2020 | 91 | 0.420 |
Why?
| | Hypoglycemia | 2 | 2014 | 427 | 0.410 |
Why?
| | Public Health | 2 | 2019 | 484 | 0.410 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 3 | 2022 | 92 | 0.410 |
Why?
| | Obesity | 2 | 2016 | 2883 | 0.400 |
Why?
| | Clinical Competence | 2 | 2017 | 1017 | 0.390 |
Why?
| | User-Computer Interface | 1 | 2013 | 149 | 0.380 |
Why?
| | Colorado | 7 | 2020 | 4421 | 0.370 |
Why?
| | Humans | 34 | 2025 | 129650 | 0.360 |
Why?
| | Hyperglycemia | 1 | 2014 | 328 | 0.360 |
Why?
| | Teaching | 1 | 2013 | 214 | 0.360 |
Why?
| | Ambulatory Care Facilities | 1 | 2012 | 228 | 0.330 |
Why?
| | Weight Loss | 5 | 2025 | 734 | 0.320 |
Why?
| | Preceptorship | 3 | 2019 | 65 | 0.290 |
Why?
| | Insulin | 2 | 2014 | 2326 | 0.280 |
Why?
| | Patient Care Team | 1 | 2012 | 605 | 0.270 |
Why?
| | Students | 2 | 2023 | 580 | 0.250 |
Why?
| | Medically Underserved Area | 2 | 2020 | 84 | 0.250 |
Why?
| | Professional-Patient Relations | 2 | 2018 | 140 | 0.220 |
Why?
| | Quality Improvement | 2 | 2023 | 1103 | 0.220 |
Why?
| | Bias | 1 | 2024 | 196 | 0.200 |
Why?
| | Osteoarthritis | 1 | 2025 | 167 | 0.200 |
Why?
| | Sugars | 1 | 2022 | 37 | 0.200 |
Why?
| | Phytotherapy | 1 | 2022 | 79 | 0.190 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2022 | 93 | 0.170 |
Why?
| | Body Weight | 2 | 2015 | 940 | 0.170 |
Why?
| | Trust | 1 | 2021 | 116 | 0.170 |
Why?
| | Dietary Supplements | 1 | 2024 | 534 | 0.160 |
Why?
| | Narration | 1 | 2020 | 57 | 0.160 |
Why?
| | Cost Savings | 1 | 2019 | 78 | 0.160 |
Why?
| | Professional Role | 2 | 2018 | 158 | 0.160 |
Why?
| | Attitude of Health Personnel | 2 | 2020 | 1098 | 0.150 |
Why?
| | Private Practice | 1 | 2018 | 21 | 0.150 |
Why?
| | Patient-Centered Care | 2 | 2013 | 505 | 0.150 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2020 | 1279 | 0.150 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3628 | 0.140 |
Why?
| | Canagliflozin | 1 | 2017 | 9 | 0.140 |
Why?
| | Glucosides | 1 | 2017 | 38 | 0.130 |
Why?
| | Benzhydryl Compounds | 1 | 2017 | 66 | 0.130 |
Why?
| | Managed Care Programs | 1 | 2017 | 133 | 0.130 |
Why?
| | Phentermine | 1 | 2016 | 9 | 0.130 |
Why?
| | Patient Care | 1 | 2017 | 109 | 0.130 |
Why?
| | Bupropion | 1 | 2016 | 40 | 0.130 |
Why?
| | Benzazepines | 1 | 2016 | 40 | 0.130 |
Why?
| | Rural Population | 1 | 2019 | 518 | 0.120 |
Why?
| | Fructose | 1 | 2016 | 106 | 0.120 |
Why?
| | Health Occupations | 1 | 2015 | 30 | 0.120 |
Why?
| | Disease Management | 1 | 2019 | 589 | 0.120 |
Why?
| | Naltrexone | 1 | 2016 | 87 | 0.120 |
Why?
| | Drug Approval | 1 | 2015 | 88 | 0.120 |
Why?
| | Drug Combinations | 1 | 2016 | 330 | 0.120 |
Why?
| | Cardiovascular Diseases | 2 | 2017 | 2004 | 0.110 |
Why?
| | Medication Adherence | 1 | 2019 | 558 | 0.110 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2014 | 39 | 0.110 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 204 | 0.110 |
Why?
| | Injections, Subcutaneous | 1 | 2014 | 147 | 0.110 |
Why?
| | Medicare | 1 | 2019 | 720 | 0.110 |
Why?
| | Glucagon-Like Peptides | 1 | 2014 | 50 | 0.110 |
Why?
| | Accountable Care Organizations | 1 | 2013 | 10 | 0.110 |
Why?
| | Cough | 1 | 2014 | 116 | 0.110 |
Why?
| | Chronic Disease | 1 | 2019 | 1720 | 0.110 |
Why?
| | Academies and Institutes | 1 | 2013 | 49 | 0.100 |
Why?
| | Forced Expiratory Volume | 1 | 2014 | 510 | 0.100 |
Why?
| | Interprofessional Relations | 1 | 2015 | 277 | 0.100 |
Why?
| | Administration, Inhalation | 1 | 2014 | 666 | 0.100 |
Why?
| | United States | 3 | 2022 | 13903 | 0.100 |
Why?
| | Self Report | 1 | 2017 | 799 | 0.100 |
Why?
| | Behavior | 1 | 2013 | 92 | 0.100 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 769 | 0.100 |
Why?
| | Professional Competence | 1 | 2012 | 94 | 0.100 |
Why?
| | Organizational Objectives | 1 | 2012 | 73 | 0.100 |
Why?
| | Recombinant Fusion Proteins | 1 | 2014 | 643 | 0.090 |
Why?
| | Drug Therapy, Combination | 1 | 2014 | 1040 | 0.090 |
Why?
| | Interdisciplinary Communication | 1 | 2012 | 186 | 0.090 |
Why?
| | Employment | 1 | 2012 | 167 | 0.090 |
Why?
| | Comorbidity | 1 | 2015 | 1547 | 0.090 |
Why?
| | Life Style | 1 | 2013 | 460 | 0.090 |
Why?
| | Retrospective Studies | 2 | 2019 | 14518 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2015 | 1368 | 0.080 |
Why?
| | Clinical Trials as Topic | 1 | 2014 | 1004 | 0.080 |
Why?
| | Health Planning Guidelines | 1 | 2009 | 25 | 0.080 |
Why?
| | Cooperative Behavior | 1 | 2012 | 433 | 0.080 |
Why?
| | Peptides | 1 | 2014 | 925 | 0.080 |
Why?
| | Learning | 1 | 2013 | 403 | 0.080 |
Why?
| | Physician's Role | 1 | 2009 | 206 | 0.070 |
Why?
| | Patient Education as Topic | 1 | 2012 | 743 | 0.070 |
Why?
| | Delivery of Health Care | 1 | 2013 | 894 | 0.060 |
Why?
| | Blood Pressure | 1 | 2012 | 1736 | 0.060 |
Why?
| | Qualitative Research | 2 | 2020 | 1235 | 0.050 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2022 | 23 | 0.050 |
Why?
| | Time Factors | 1 | 2013 | 6556 | 0.050 |
Why?
| | Biomarkers | 1 | 2012 | 3973 | 0.040 |
Why?
| | Anecdotes as Topic | 1 | 2020 | 7 | 0.040 |
Why?
| | Competitive Behavior | 1 | 2020 | 41 | 0.040 |
Why?
| | Adult | 1 | 2022 | 35576 | 0.040 |
Why?
| | Self Concept | 1 | 2020 | 242 | 0.040 |
Why?
| | Benchmarking | 1 | 2019 | 176 | 0.040 |
Why?
| | Focus Groups | 1 | 2020 | 453 | 0.030 |
Why?
| | Accreditation | 1 | 2017 | 80 | 0.030 |
Why?
| | Interpersonal Relations | 1 | 2020 | 392 | 0.030 |
Why?
| | Research Report | 1 | 2015 | 76 | 0.030 |
Why?
| | Emotions | 1 | 2020 | 538 | 0.030 |
Why?
| | Faculty | 1 | 2015 | 137 | 0.030 |
Why?
| | Schools, Pharmacy | 1 | 2013 | 46 | 0.030 |
Why?
| | Community Networks | 1 | 2013 | 56 | 0.030 |
Why?
| | Pharmacy Service, Hospital | 1 | 2013 | 90 | 0.020 |
Why?
| | Data Collection | 1 | 2012 | 650 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 5406 | 0.020 |
Why?
| | Internship and Residency | 1 | 2017 | 1053 | 0.020 |
Why?
| | Communication | 1 | 2012 | 846 | 0.020 |
Why?
| | Animals | 1 | 2025 | 35361 | 0.010 |
Why?
| | Male | 1 | 2020 | 63681 | 0.010 |
Why?
| | Female | 1 | 2020 | 68776 | 0.010 |
Why?
|
|
Nuffer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|